MACD
Previous Close | 9.41 |
Open | 9.41 |
Bid | 9.49 x 1800 |
Ask | 9.48 x 800 |
Day's Range | 9.28 - 9.54 |
52 Week Range | 8.18 - 24.74 |
Volume | |
Avg. Volume | 338,850 |
Market Cap | 371.176M |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.96 |
Earnings Date | Jul 10, 2023 - Jul 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.50 |
ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.
Dutch Bros, Chegg, Impinj and AngioDynamics are part of the Zacks Screen of the Week article.
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.
AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.
Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
LATHAM, N.Y., April 11, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Needham 22nd Annual Virtual Healthcare Conference at 8:00
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
This arguably was demonstrated when shares of medical device maker AngioDynamics (NASDAQ: ANGO) plummeted 27% on the day of its fiscal third-quarter earnings release recently. With a $400 million market capitalization, AngioDynamics is one of the smaller publicly traded medical device companies. AngioDynamics' product lineup includes NanoKnife, a minimally invasive treatment utilized in patients with inoperable or late-stage cancers.
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2023 Earnings Call Transcript March 30, 2023 Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. […]
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
LATHAM, N.Y., March 30, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2023, which ended February 28, 2023.
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
LATHAM, N.Y., March 13, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same da
LATHAM, N.Y., February 28, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in the following three investor conferences in March:
Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
Within that last group sits AngioDynamics (NASDAQ: ANGO), a little-known company that makes devices for treating peripheral vascular disease. Let's dig into AngioDynamics' fundamentals and valuation to address this question. With a market capitalization of just $539 million, AngioDynamics is a medtech business that flies under the radar of most retail investors.
AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call Transcript January 5, 2023 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.01. Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Second Quarter Earnings Call. At this time all participants are in listen-only-mode. A question-and-answer session will follow the formal presentation. As […]
AngioDynamics ( NASDAQ:ANGO ) Second Quarter 2023 Results Key Financial Results Revenue: US$85.4m (up 9.1% from 2Q...
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.
The Latham manufacturer is in the midst of a multiyear shift away from lower-margin legacy products as CEO Jim Clemmer has refocused the business around the development higher-margin technology to combat blood clots and tumors.
AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
LATHAM, N.Y., January 05, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2023, which ended November 30, 2022.
SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.